4564.T OncoTherapy Science (JPX) at JPY 21.00 intraday: 34.22M shares traded signals active interest

The 4564.T stock of OncoTherapy Science, Inc. is trading at JPY 21.00 intraday on JPX on 20 Feb 2026 with 34,217,200 shares changing hands, ranking it among the most active names on the session. Volume has driven a move between a day low JPY 21.00 and day high JPY 22.00, while the year range sits at JPY 19.00–35.00. Market attention is tied to the company’s late‑stage vaccine program and ongoing small‑molecule oncology trials, which are the primary catalysts moving price and liquidity today.

Intraday flow and trading metrics for 4564.T stock

OncoTherapy Science (4564.T) is the session’s most active healthcare name on JPX with volume 34,217,200.00 and average volume 47,144,176.00. The stock opened at JPY 22.00 and trades near JPY 21.00, with a 50‑day average JPY 20.94 and 200‑day average JPY 24.08, indicating short‑term interest but longer‑term consolidation.

Fundamentals and valuation: 4564.T stock financial snapshot

OncoTherapy posts EPS -2.83 and PE -7.42, reflecting negative earnings while revenue per share is 2.17 and cash per share is 6.06. Key ratios show a strong liquidity buffer with current ratio 8.51 and PB 3.54, but price‑to‑sales 9.20 and EV/Sales 6.43 indicate a valuation premium versus peers in Japan’s healthcare sector.

Clinical pipeline catalysts driving 4564.T stock moves

Pipeline progress for candidates such as S‑588410 (Phase III esophageal cancer) and OTS167 (Phase I/II leukemia) is the primary news driver for 4564.T stock. Any trial readouts or regulatory steps tied to those programs typically produce outsized intraday volume and volatility for the company on JPX.

Technicals and trading signals for 4564.T stock

Short‑term indicators for 4564.T stock are mixed: RSI 52.77 suggests neutral momentum, MACD histogram 0.12 shows mild bullish tilt, and ATR 1.29 points to modest intraday volatility. Bollinger Bands run JPY 19.37–21.73 and CCI 183.01 flags a near‑term overbought condition that traders should watch.

Meyka AI grade and model forecast for 4564.T stock

Meyka AI rates 4564.T with a score out of 100 as 69.18 | Grade B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a yearly price JPY 18.02, which represents an implied -14.18% vs current JPY 21.00; monthly projection JPY 16.39 implies -21.95%. Forecasts are model‑based projections and not guarantees.

Risks, sector context and trading strategy for 4564.T stock

Risks include continued negative EPS, clinical trial setbacks and valuation dispersion versus larger healthcare peers where avg PE is 23.48 in Japan’s sector. For intraday traders, tight risk controls matter: watch volume spikes, the JPY 19.00 support level (year low) and JPY 22.00 short‑term resistance; for investors, monitor upcoming earnings and trial milestones before adjusting exposure.

Final Thoughts

4564.T stock is one of today’s most active JPX names, trading JPY 21.00 with 34.22M shares intraday on 20 Feb 2026 and showing mixed signals between short‑term interest and medium‑term consolidation. Fundamentals show negative EPS -2.83 and elevated P/S 9.20, while balance sheet liquidity (current ratio 8.51, cash per share 6.06) reduces immediate solvency risk. Meyka AI’s forecast model projects a yearly target JPY 18.02, implying -14.18% from the current price; alternative monthly projection is JPY 16.39. Our view: intraday traders can exploit volume‑driven moves, while longer‑term investors should wait for clinical or earnings clarity. Meyka AI, an AI‑powered market analysis platform, provides real‑time tools and model outputs to help track these catalysts. Forecasts are model‑based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.